| Private Placement / Financing Transactions
SHINE Technologies: The company received $122.5 million of development capital from undisclosed investors on April 21, 2025. The company is a developer of medical isotopes designed to serve energy, aerospace, manufacturing, medicine, and nuclear industries.
Biolinq: The company raised $100 million of Series C venture funding in a deal led by Alpha Wave Global on April 22, 2025, putting the company’s pre-money valuation at $305 million. M Ventures, Hikma Ventures, LifeSci Venture Partners, RiverVest Venture Partners, Features Capital, AXA IM Alts, Aphelion Capital and Taisho Pharmaceutical Holdings also participated in the round. The company is a developer of a precision multi-analyte wearable sensor to improve metabolic health.
Anumana: The company raised an estimated $95.4 million of Series C venture funding from Mayo Clinic, Boston Scientific and Matrix on April 24, 2025, putting the company’s pre-money valuation at $484.6 million. NTTVC and Matrix Capital Management also participated in the round. The company is a developer of an AI-driven medical technology intended to enhance early diagnosis and intervention in cardiovascular care.
Noveome Biotherapeutics: The company raised $51 million of Series E venture funding in a deal led by MAK Capital on April 23, 2025. UPMC Enterprises, Lancet Capital, Miraki Innovation, Terence Golden, Redevelopment Authority of Allegheny County, Commonwealth of Pennsylvania, University of Pittsburgh Endowment and Carnegie Mellon University also participated in the round. The company is a developer of novel biotherapeutic products designed to treat inflamed or damaged tissues.
Field Medical: The company raised $40 million of Series A venture funding from undisclosed investors on April 21, 2025, putting the company’s pre-money valuation at $55 million. Of the total funding, $20 million was raised in the form of convertible debt which was converted to equity. The company is a developer of pulsed field ablation technology.
LTZ Therapeutics: The company raised $40 million of Series A venture funding in a deal led by Wanwu Growth Venture Capital and Zoo Capital on April 24, 2025. Lapam Capital, GL Ventures, 5Y Capital, Lanchi Ventures, Unicorn Capital Partners and Institute for Follicular Lymphoma Innovation also participated in the round. The company is a developer of novel immunotherapies designed to treat patients suffering from cancer and other diseases.
Grove Biopharma: The company raised $36 million of venture funding in a deal led by DCVC Bio on April 23, 2025, putting the company’s pre-money valuation at $28 million. Eli Lilly and Company, Gradiant, Mansueto Investments, InVivium Capital, Portal Innovations and Walder Ventures also participated in the round. The company is an operator of a modality biotechnology business intended to treat unmet medical needs in oncology, chronic inflammatory, and neurodegenerative diseases.
Superpower: The company raised $30 million of Series A venture funding and debt in a deal led by Forerunner Ventures on April 22, 2025, putting the company’s pre-money valuation at $120 million. Susa Ventures, The Family Fund, Opal Ventures, Long Journey Ventures, Visible Ventures, Valia Ventures, Day One Ventures, Vanessa Hudgens, Steve Aoki, Giannis Antetokounmpo, Starting Line and Winklevoss Capital Management also participated in the round. The company is a developer of a digital clinic designed for personalized healthcare.
Abrexa Pharmaceuticals: The company raised $23 million of venture funding from undisclosed investors on April 24, 2025. The company is a developer of novel drugs designed to treat Alzheimer’s disease.
Apnimed: The company raised $16.5 million of venture funding from undisclosed investors on April 24, 2025. The company is a developer of a pharmacologic therapy designed to target, with orally dosed medicines, the key underlying neurobiological mechanisms that lead to airway obstruction.
ProNova Solutions: The company raised $13.5 million of Series Seed venture funding from JLS Fund on April 25, 2025. The company is a developer of a compact proton therapy system designed to expand global access to advanced cancer treatment.
Centerline Biomedical: The company raised $10.8 million of venture funding from undisclosed investors on April 24, 2025. The company is a developer of a three-dimensional visualization and real-time navigation system designed to improve endovascular procedures and reduce radiation exposure.
Ascertain: The company raised $10 million of Series A venture funding in a deal led by Deerfield Management on April 22, 2025. Northwell Health and other undisclosed investors also participated in the round. The company is a developer of an AI-powered healthcare platform designed to improve the quality and efficiency of patient care.
Cipher Surgical: The company raised $10 million of Series A venture funding in a deal led by Medical Solutions (MSI) on April 25, 2025. The company is a provider of surgical medical devices intended to help surgeons maintain a clear distal window of the laparoscope.
Akadeum Life Sciences: The company raised $6.1 million of venture funding from NYBC Ventures and other undisclosed investors on April 25, 2025. The company is a developer of bio-separation products designed to facilitate the removal of target cells from biological samples.
DMC Biotechnologies: The company raised $4.8 million of venture funding through a combination of equity and convertible debt from undisclosed investors on April 22, 2025. The company is a biomanufacturer that uses precision fermentation to create chemical ingredients.
Galaxy Diagnostics: The company raised $4.1 million of Series A venture funding from undisclosed investors on April 22, 2025, putting the company’s pre-money valuation at $20.9 million. The company is a developer of diagnostic tests intended for early-stage disease detection.
PhAST: The company raised $3.4 million of venture funding from undisclosed investors on April 24, 2025. The company is an operator of a healthcare technology business developing artificial intelligence-powered diagnostic systems to combat antibiotic resistance.
Deepcell: The company raised an undisclosed amount of venture funding from Fifty Years on April 24, 2025. The company is a developer of a microfluidic imaging platform designed to offer non-invasive genetic tests with diagnostic-level accuracy.
Ostro: The company raised an undisclosed amount of venture funding from Havas Media Network on April 24, 2025. The company is an operator of a patient engagement and telemedicine platform.
Repairon: The company raised an undisclosed amount of venture funding from Bioventure on April 23, 2025. The company is a developer of tissue engineering technologies designed to repair failing organs.
|
